What does Larimar Therapeutics, Inc. do?
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare,…
What is Larimar Therapeutics, Inc.'s P/E and P/B ratio?
Larimar Therapeutics, Inc. has a P/E ratio of -1.1 and a P/B ratio of 1.85.
What is Larimar Therapeutics, Inc.'s debt-to-equity ratio?
Larimar Therapeutics, Inc. has a debt-to-equity ratio of 0.04.
How much does Larimar Therapeutics, Inc. owe compared with what it owns?
Larimar Therapeutics, Inc. owes $0.23 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Larimar Therapeutics, Inc.'s Positivity rank?
Larimar Therapeutics, Inc. is ranked #2,676 of 6,775 companies globally and #892 of 4,000 in United States on PositoAI, with a Positivity Score of 21,314.
Does Larimar Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Larimar Therapeutics, Inc..
Where can I read the latest news about Larimar Therapeutics, Inc.?
Recent headlines about Larimar Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Larimar Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Larimar Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.